TY - JOUR
T1 - Synergistic interaction of diclofenac, benfotiamine, and resveratrol in experimental acute pain
AU - Montiel-Ruiz, Rosa Mariana
AU - Granados-Soto, Vinicio
AU - García-Jiménez, Sara
AU - Reyes-García, Gerardo
AU - Flores-Murrieta, Francisco J.
AU - Déciga-Campos, Myrna
PY - 2011/8
Y1 - 2011/8
N2 - This study was designed to evaluate the possible synergistic antinociceptive interactions between diclofenac, benfotiamine, and resveratrol on acetic acid-induced nociception in mice. Isobolographic analyses were used to define the nature of the interactions between drugs. Diclofenac, benfotiamine, or resveratrol, as well as their combinations, produced a dose-dependent antinociceptive effect. ED30 values were estimated for the individual drugs and isobolograms were constructed. Theoretical ED30 values for the combinations estimated from the isobolograms were 170.9±23.4, 4.9±1.0, and 173.3±11.8 mg/kg for the diclofenac+benfotiamine, diclofenac+resveratrol, or benfotiamine+resveratrol combination, respectively. These values were significantly higher than the actually observed ED 30 values, which were 10.2±1.9, 0.3±0.1, and 5.3±0.8 mg/kg, respectively, indicating a synergistic interaction in the three combinations. Data indicate that low doses of the diclofenac+benfotiamine, diclofenac+resveratrol, or benfotiamine+resveratrol combination can interact synergistically to reverse acetic acid-induced nociception and they may represent a therapeutic advantage for clinical treatment of inflammatory pain.
AB - This study was designed to evaluate the possible synergistic antinociceptive interactions between diclofenac, benfotiamine, and resveratrol on acetic acid-induced nociception in mice. Isobolographic analyses were used to define the nature of the interactions between drugs. Diclofenac, benfotiamine, or resveratrol, as well as their combinations, produced a dose-dependent antinociceptive effect. ED30 values were estimated for the individual drugs and isobolograms were constructed. Theoretical ED30 values for the combinations estimated from the isobolograms were 170.9±23.4, 4.9±1.0, and 173.3±11.8 mg/kg for the diclofenac+benfotiamine, diclofenac+resveratrol, or benfotiamine+resveratrol combination, respectively. These values were significantly higher than the actually observed ED 30 values, which were 10.2±1.9, 0.3±0.1, and 5.3±0.8 mg/kg, respectively, indicating a synergistic interaction in the three combinations. Data indicate that low doses of the diclofenac+benfotiamine, diclofenac+resveratrol, or benfotiamine+resveratrol combination can interact synergistically to reverse acetic acid-induced nociception and they may represent a therapeutic advantage for clinical treatment of inflammatory pain.
KW - antinociception
KW - benfotiamine
KW - diclofenac
KW - resveratrol
KW - synergism
UR - http://www.scopus.com/inward/record.url?scp=80052041190&partnerID=8YFLogxK
U2 - 10.1002/ddr.20441
DO - 10.1002/ddr.20441
M3 - Artículo
SN - 0272-4391
VL - 72
SP - 397
EP - 404
JO - Drug Development Research
JF - Drug Development Research
IS - 5
ER -